Pasithea
KTTA
Pasithea (KTTA) news
Recent news
Pasithea Therapeutics Corp - protocol amendment extends dose escalation up to 52mg for PAS-4
AInvest Wire · Jun 30, 2026PASITHEA THERAPEUTICS CORP - PAS-4 shows favorable safety profile with only grade 1 or 2 adverse events
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has reported favorable safety findings for its lead candidate, PAS-004, in early-stage clinical trials. According to interim results from the Phase 1 trial, no dose-limiting toxicities or treatment-related adverse events (TRAEs) have been observed in the…
AInvest Wire · Jun 30, 2026PASITHEA THERAPEUTICS - ON TRACK TO RELEASE INTERIM NF1 DATA UPDATE IN Q4 2026
AInvest Wire · Jun 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.